Archives
-
Recombinant Human Growth Hormone Research Workflow
2026-08-25
Build reproducible chondrocyte proliferation, differentiation, and signaling experiments with a well-characterized somatotropin reagent. This workflow connects dose-response testing to the IGFBP2–THBS1–IGF-1 axis while providing practical controls and troubleshooting guidance.
-
Melatonin, Autophagy, and Hypertrophic Scars
2026-08-25
The reference study identifies MT2-dependent suppression of PI3K/Akt/mTOR signaling as a mechanism by which melatonin enhances autophagy and restrains hypertrophic-scar fibroblast activity. Its combination of primary human fibroblast experiments, pathway perturbation, transcriptomics, and a rabbit-ear model provides a mechanistic framework for evaluating autophagy as an anti-fibrotic target.
-
4-Hydroxytamoxifen Protocol and QC Guide
2026-08-24
4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled in vitro research, including breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. It should not be selected for workflows that require ethanol or aqueous dissolution, and the supplied dossier does not establish assay-specific dose-response results.
-
4Q Design for Stable mRNA Delivery Vectors
2026-08-24
The 2024 Chemistry of Materials study introduces a 4Q framework that separates mRNA delivery into vector stability, diffusion, cellular entry, and intracellular release. Its polycatechol-based PBD system combines reversible intracellular degradation with room-temperature polyplex stability, producing substantially stronger in vivo reporter expression than a jetPEI comparator.
-
Podophyllotoxin Derivative 5p Overcomes MDR
2026-08-23
A 2024 European Journal of Pharmacology study shows that podophyllotoxin derivative 5p combines topoisomerase IIα catalytic inhibition with microtubule-polymerization inhibition. This dual mechanism was associated with reduced drug-resistance phenotypes, G2/M arrest, apoptosis, pyroptosis-related signaling, and suppression of resistant tumor growth in cellular and xenograft models.
-
PP 2 (AG 1879) for Src Pathway Research
2026-08-22
PP 2 (AG 1879) provides a practical way to test Src-family kinase dependence in cancer, immune-cell, and cytoskeletal assays. This guide connects its nanomolar biochemical potency with experimental workflows, controls, and troubleshooting strategies for reproducible pathway interpretation.
-
Gap19: From Cx43 Signaling to Neuroprotection
2026-08-22
Gap19 is a selective connexin 43 hemichannel blocker that helps translational researchers separate stress-responsive hemichannel signaling from gap junction communication. This article connects Cx43-mediated ATP release, neuroglial injury biology, macrophage inflammatory signaling, and ischemic stroke research while outlining evidence-aware experimental strategies.
-
Aurora A, SAM Metabolism, and Trained Immunity
2026-08-21
Li et al. identify Aurora kinase A as a metabolic and epigenetic regulator of β-glucan-trained immunity, rather than solely a mitotic kinase. Their data connect Aurora A inhibition to the mTOR–FOXO3–GNMT axis, reduced endogenous S-adenosylmethionine, altered histone methylation, and weakened inflammatory recall, with consequences for β-glucan-associated tumor control.
-
Cy3 NHS ester (non-sulfonated): Practical Guide
2026-08-20
Cy3 NHS ester (non-sulfonated) provides an orange fluorescent NHS ester for labeling amine-containing proteins, peptides, oligonucleotides, and DNA when a controlled organic co-solvent is acceptable. Its water insolubility makes it unsuitable for aqueous-only preparation and may limit use with solvent-sensitive biomolecules unless the formulation and cleanup are carefully validated.
-
4-Hydroxytamoxifen: Practical Protocol Guide
2026-08-20
This guide explains how to prepare, store, and quality-check 4-Hydroxytamoxifen (SKU B6167) for DMSO-based receptor, cancer, cardiac myocyte, and related cell workflows. It is appropriate for controlled research use but should not be selected for protocols requiring water- or ethanol-soluble stock solutions.
-
LY2886721: A Precision BACE Inhibitor Roadmap
2026-08-19
A translational framework for using LY2886721 to investigate BACE1 biology, amyloid beta reduction, synaptic safety, and exposure-aware study design in Alzheimer’s disease research.
-
FAK Inhibitor 14: Applied Research Workflows
2026-08-19
FAK Inhibitor 14 enables controlled dissection of FAK-driven adhesion, migration, and EMT in cancer models. This practical guide connects reagent handling with cholesterol-resistance experiments, pathway-focused controls, and troubleshooting strategies for reproducible cell migration inhibition.
-
Bacitracin (B1670): Lab Protocol Guide
2026-08-18
Bacitracin (B1670) provides a research reagent for studying bacterial growth inhibition associated with cell wall and peptidoglycan synthesis disruption. It is intended for controlled antibacterial research workflows only and should not be used for diagnostic, clinical, or medical applications.
-
Bovine Ovarian Heterogeneity, Redox Stress, and Apoptosis
2026-08-18
This study shows that simple morphology-based classification of bovine ovaries corresponds to coordinated redox imbalance and apoptotic activation in ovarian tissue, follicular fluid, and granulosa cells. Its cross-compartment design identifies granulosa cells as the most sensitive functional readout and offers a practical strategy for reducing biological variability in cattle assisted reproductive technology studies.
-
4-Hydroxytamoxifen: Protocol Parameters and QC
2026-08-17
4-Hydroxytamoxifen provides a DMSO-compatible estrogen receptor modulator for controlled cell, cardiac myocyte, and cancer research workflows. It should not be selected for protocols that require water or ethanol dissolution, and solution storage should be minimized to protect reproducibility.